PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade

Summary Clinical trials have now identified over 30 cancer histotypes with sensitivity to anti-PD-(L)1 therapies. It is the first time in oncology that a class of drugs has demonstrated such a wide spectrum of activity in monotherapy. This subgroup of cancers (‘PD-Lomas’) is driving the clinical res...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2019-01, Vol.120 (1), p.3-5
Main Authors: Hirsch, Laure, Zitvogel, Laurence, Eggermont, Alexander, Marabelle, Aurelien
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - immunology
Antibodies, Monoclonal - therapeutic use
B7-H1 Antigen - antagonists & inhibitors
B7-H1 Antigen - immunology
Biomedical and Life Sciences
Biomedicine
Cancer
Cancer Research
Clinical trials
Clinical Trials as Topic
Drug Resistance
Editorial
Epidemiology
Humans
Immunotherapy
Molecular Medicine
Neoplasms - classification
Neoplasms - genetics
Neoplasms - immunology
Neoplasms - therapy
Oncology
PD-1 protein
PD-L1 protein
Programmed Cell Death 1 Receptor - antagonists & inhibitors
Programmed Cell Death 1 Receptor - immunology
Sensitivity
Signal Transduction
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Clinical trials have now identified over 30 cancer histotypes with sensitivity to anti-PD-(L)1 therapies. It is the first time in oncology that a class of drugs has demonstrated such a wide spectrum of activity in monotherapy. This subgroup of cancers (‘PD-Lomas’) is driving the clinical research strategies for the next generation of combination immunotherapy.
ISSN:0007-0920
1532-1827
DOI:10.1038/s41416-018-0294-4